Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in Korea

Background. Cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp) affect the bioavailability of tacrolimus, the most commonly used immunosuppressive agent in organ transplant recipients. We have determined the genotypic frequencies of the CYP3A and ATP-binding cassette sub-family B member 1 (ABCB1) genes, which encode the CYP3A and P-gp proteins, respectively, in Korean organ transplant recipients and donors, and have assessed the influence of CYP3A and ABCB1 polymorphisms on tacrolimus concentrations. Methods. Using chip-based MALDI-TOF mass spectrometry, 506 solid organ transplant recipients and 62 corresponding of liver transplant donors were genotyped for CYP3A4*6, CYP3A4*18, CYP3A5*3, CYP3A5P1*3, ABCB1 c.2677G>A/T, and ABCB1 c.3435C>T alleles, and their steady-state blood concentrations of tacrolimus were measured. Results. Frequencies of variant alleles among the transplant recipients were CYP3A5*3 76.8%, CYP3A5P1*3 75.9%, ABCB1 c.2677A/T 52.8%, ABCB1 c.3435T 36.9%, CYP3A4*18 1.9%, and CYP3A4*6 0.3%. The CYP3A5P1*3 allele was strongly linked to the CYP3A5*3 allele (r2=0.816). Patients with the CYP3A5*3 and CYP3A5P1*3 alleles showed higher blood tacrolimus concentrations per adjusted dose ratio than did patients with wild-type alleles, among both liver transplant donors and renal transplant recipients. Conclusion. The CYP3A5 genotype of the liver is considered to show the most important association with tacrolimus concentrations. Ultimately, genotyping for CYP3A5 may help optimal individualization of immunosuppressive drug therapy for patients undergoing solid organ transplantation.

[1]  Kyungsoo Park,et al.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. , 2007, British journal of clinical pharmacology.

[2]  Satohiro Masuda,et al.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, Pharmacology & therapeutics.

[3]  S. Uemoto,et al.  Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living‐donor liver transplant recipients , 2006, Clinical pharmacology and therapeutics.

[4]  Shu-sen Zheng,et al.  Genetic factors for individual administration of immunosuppressants in organ transplantation. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.

[5]  Haiyang Xie,et al.  Influence of CYP3A5 Gene Polymorphisms of Donor Rather than Recipient to Tacrolimus Individual Dose Requirement in Liver Transplantation , 2006, Transplantation.

[6]  J. Squifflet,et al.  Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids , 2005, Transplantation.

[7]  Zhi-Hong Liu,et al.  Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation , 2005, Clinical transplantation.

[8]  M. Ingelman-Sundberg,et al.  A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1* , 2005, Journal of Biological Chemistry.

[9]  D. Lu,et al.  Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls , 2005, Neuroscience Letters.

[10]  T. Habuchi,et al.  Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.

[11]  Qi Li,et al.  Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. , 2005, Transplantation proceedings.

[12]  First Mr.  Tacrolimus based immunosuppression. , 2004 .

[13]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[14]  M. First.  Tacrolimus based immunosuppression. , 2004, Journal of nephrology.

[15]  N. Kamatani,et al.  Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population , 2003, Human mutation.

[16]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[17]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Kim.  MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. , 2002, Pharmacogenetics.

[19]  S. Uemoto,et al.  C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. , 2002, Pharmacogenetics.

[20]  Zhaoqian Liu,et al.  Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. , 2002, Acta pharmacologica Sinica.

[21]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[22]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[23]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[24]  M. Lai,et al.  Novel mutations of CYP3A4 in Chinese. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[25]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.